| Nov 7 |
PepGen GAAP EPS of -$0.66 beats by $0.21
|
| Nov 7 |
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Nov 4 |
PepGen to Participate in Upcoming Investor Conferences
|
| Oct 1 |
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
|
| Sep 19 |
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
|
| Aug 20 |
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
|
| Aug 20 |
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
|
| Aug 9 |
PepGen GAAP EPS of -$0.87
|
| Aug 8 |
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Aug 2 |
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen
|
